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Background 
 
 Staphylococcus aureus and antimicrobial resistance 
Staphylococcus aureus (SA) has been considered a potential pathogen since its 
discovery in 1880, and before the introduction of penicillin the mortality rate of 
patients with an infection caused by SA was about 80%. In 1942 the first penicillin-
resistant strain emerged, and in 1960 almost 80% of all S. aureus (SA) strains 
resulted to be resistant to this antimicrobial agent. The introduction of methicillin 
dates from 1959, and two years later the first resistant strain (methicillin-resistant 
Staphylococcus aureus, MRSA) was isolated. During the next decades MRSA 
clones disseminated worldwide. This great ability to develop antimicrobial resistance 
led to the first isolation of vancomycin intermediate SA strain (VISA), as well as 
resistant strains (vancomycin resistant MRSA, VRSA), generated by the intensive 
selective pressure caused leading to intermediate phenotypes not inhibited in vitro 
at concentrations due to the more intensive vancomycin use1. To date, at least nine 
VRSA have been reported in USA2. No resistance to glycopeptides was detected in 
Italy during 2012; moreover, all MRSA isolates were susceptible to tigecycline and  
linezolid3. VISA strains isolated in bacteremia and endocarditis were described in 
Italy in 20123. 
The last European Antimicrobial Resistance Surveillance (EARS) report highlighted 
a significant increasing trend of MRSA proportions in Italy (www.ecdc.europa.eu), 
whilst the countries showing a more evident and sustained decrease of MRSA 
proportion were Austria, Cyprus, Estonia, France, Ireland, Latvia and UK3. 
 Differences in antimicrobial resistance patterns are described between community-
acquired MRSA (CA-MRSA) and hospital-acquired MRSA (HA-MRSA), being the 
latter often multi-drug resistant (MDR). CA-MRSA isolates may present different 
sensitivity patterns to antimicrobial agents, being usually sensitive to clindamycin in 
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US, gentamicin in Australia, ciprofloxacin in England2. Italian data concerning cystic 
fibrosis (CF) patients reported similar resistance rates HA- and CA-MRSA, with a 
statistically significant difference in gentamycin sensitivity4. 
 
Community-acquired MRSA (CA-MRSA), Hospital-acquired MRSA (HA-
MRSA), Livestock-associated MRSA (LA-MRSA) 
In 2000, the Centers for Disease Control and Prevention (CDC) stated that a case of 
MRSA infection could be defined “community-acquired” if diagnosed in an out-
patient, or within 48 hour of hospitalization when traditional risk factors for MRSA 
infection are lacking. On the other hand, an infection was considered “hospital 
acquired” in in-patients, or when diagnosed after the receipt of hemodialysis, 
surgery, residence in long-term facilities or hospitalization during the previous year,  
the presence of catheters or percutaneous devices, previous isolation of MRSA, as 
reported by David and Daum2. Recent studies demonstrated that defining CA-MRSA 
on the basis of the lack of exposure to risk factors allowed the misidentification of a 
large part of CA-MRSA infections; to date, CA-MRSA and HA-MRSA are 
distinguished by means of genetic determinants, but these definitions were starting 
to blur since 20032. The Staphylococcal Chromosome Cassette mec (SCCmec) is 
the genetic determinant on the basis of which it is possible to correctly discriminate 
between CA-MRSA and HA-MRSA. SCCmec is a mobile genomic island containing 
genes encoding various determinants of resistance both to antimicrobial agents, and 
to other compounds. This genomic island contains the mecA gene, which encodes 
the penicillin-binding protein conferring resistance to methicillin as well as to β-
lactams. The mec complex, ccr genes and junkyard regions represent the basic 
structure of the SCCmec element. The combination of mec and ccr genes and 
junkyard regions plus the above-mentioned mobile elements are able to confer 
different characteristics to the different SCCmec types. 
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To date SCCmec types from I to XI have been classified, as recently described by 
Hiramatsu and colleagues5. HA-MRSA are currently associated with SCCmec type I, 
II, III and VIII, and CA-MRSA are mainly represented by types IV, V, VI and VII. 
Each SCCmec type is characterized by different size and associated genetic 
determinants which confer different antimicrobial resistance profiles. Insertion 
sequences, transposons, plasmids are often encoded by SCCmec genomic islands. 
HA-MRSA are often multi-drug resistant germs, whilst CA-MRSA appear to be less 
resistant to antimicrobial agents than virulent. A correct discrimination between CA- 
and HA-MRSA is crucial to obtain a better understanding of epidemiology and 
strains diffusion since CA-MRSA started to spread in hospital settings, representing 
a further threat for hospitalized patients due to their virulence. Moreover, some 
community-onset infections are caused by HA-MRSA strains, probably related to the 
management at home of complex HA-MRSA infections 2. 
There is an additional type of MRSA: livestock-associated (LA) MRSA were recently 
described. These strains were first associated with human disease in 2003, when a 
MRSA clone associated with reservoir in pigs was isolated from a human. This 
particular clone has a peculiar genetic background, and is characterized by the 
impossibility to obtain a pulsed field gel electrophoresis (PFGE) profile. To date, this 
clone was described in the Netherlands, Belgium, Europe, Asia and United States6, 
constituting another challenge for physicians and microbiologists.  
The additional step to properly characterize MRSA strains is to determine their  
sequence type (ST) using Multi Locus Sequence Typing (MLST) analysis because 
at the moment, the nomenclature of MRSA is based on the combination of ST and 
SCCmec type data7. MLST analysis allows to assign a clone basing on partial 
sequencing of seven different house-keeping genes, being each sequence assigned 
as a distinct allele. MLST allows also to determine clonal complexes (CCs), defined 
as groups of strains sharing five of the seven house-keeping genes used for MLST 
analysis8. 
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Molecular epidemiology of MRSA strains 
An increased knowledge of MRSA clones distribution is crucial to avoid the spread 
of virulent lineage and to monitor global epidemiology in order to set up more 
efficacious infection control measures and therapies. MRSA epidemiology drastically 
has changed during the last years, due to the spreading of CA-MRSA lineages: 
since the early 1990s, many CA-MRSA clones disseminated worldwide. CA-MRSA 
has recently started to replace HA-MRSA in hospital settings, especially in areas 
where CA-MRSA prevalence is high7. A limited number of both HA- and CA-MRSA 
lineages has spread since 1961, when the first MRSA emerged7. Major HA-MRSA 
clones are represented by STs 250, 45, 239, 247, 8, 5, 228, 22, 36, important 
lineages belonging to CC 5, 8, 22, 36, 45. Five major CA-MRSA clones are widely 
worldwide diffused: European clone ST80-MRSA-IV; Soutwest Pacific clone ST30- 
MRSA-IV, USA 400 ST1-MRSA-IV; USA 300 ST8-MRSA-IV; USA1000 ST59- 
MRSA-IV or VII7. An accurate description of MRSA global epidemiology and CCs 
diffusion was published by Monecke and colleagues in 20119.  CC1 includes several 
strains of CA-MRSA, diffused in Europe, Australia, Egypt and US. CC5 and CC8 
represent common and widespread clonal complexes, comprising a large number of 
both HA- and CA-MRSA strains. CC22 is common and largely diffused, including 
pandemic clones such as ST22-MRSA-IV. Several HA- and CA-MRSA originated 
from CC30, including the pandemic Soutwest Pacific clone ST30- MRSA-IV. CC45 
strains cluster into two distinct groups, being this CC one of the major MRSA 
lineages. A recent European study10 defined a high percentage of community-
associated clones, both MRSA and MSSA. Most MRSA were related to USA 300 
genetic background (ST8-MRSA-IV), followed by European clone (ST80-MRSA-IV) 
and Taiwan clone (ST59-MRSA-IV). A surprising high genetic diversity among 
MRSA was highlighted, describing also novel associations between genetic 
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background and SCCmec10. Different SA lineages appear to be evolved 
independently due to the presence of two different systems of restriction-
modifications, avoiding uptake of DNA originated from different bacterial species 
and also from other SA lineages. Therefore, strains belonging to different lineages 
possess a unique but highly conserved combination of genes and their regulators11.  
Nowadays Italian data concerning molecular epidemiology of MRSA represent an 
important tool to improve infection control measures. A few reports describing the 
peculiar situation of outbreaks or particular regions are currently available12,13,14, and 
it was recently demonstrated that in some European countries epidemic MRSA 
clones are in replacement. Recent work by Campanile and colleagues showed the 
changing epidemiology of HA-MRSA Italian isolates during a long period of time15. 
The majority of MRSA clones belonged to six major clones: ST8-MRSA-I, ST247-
MRSA-I, ST239-MRSA-III, ST228-MRSA-I, ST22-MRSA-IV, and their prevalence 
varied from 1990s to 200715. ST228-MRSA-I increased its presence during the 
period between 1990 and 200715, while  to date Southern Germany clone ST228-
MRSA-I was replaced by ST22- MRSA-IV due to its ability to produce bio-film and to 
inhibit ST228-MRSA I growth in co-culture16. The genetic background of CA-MRSA 
and HA-MRSA, their transmissibility, antibiotic susceptibility and virulence have 
been poorly investigated in pediatric patients in Italy and there is little data regarding 
CA-MRSA or HA-MRSA in pediatric intensive care units and high risk wards.  
 
Cystic Fibrosis and MRSA 
Cystic fibrosis (CF) is the most common autosomal inherited disorder in the 
Caucasian population. It is a multisystem disorder resulting from a disruption in 
chloride transport at the cellular level leading to abnormal dehydrated secretions in 
the lungs. This results in impaired mucociliary clearance leading to recurrent 
pulmonary infections, bronchiectasis and progressively deteriorating lung function, 
which is the main cause of morbility and mortality for CF patients17. The bacterial 
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species most commonly associated with respiratory tract infection in CF include 
common human pathogens such as SA and Haemophilus influenzae as well as 
several opportunistic pathogens, the most important of which is Pseudomonas 
aeruginosa, and nosocomial pathogens such as Stenotrophomonas maltophilia and 
Achromobacter xylosoxidans. Other species that are only occasionally associated 
with human infections apart from CF, are Burkholderia cepacia complex, 
Burkholderia gladioli, Ralstonia species, Cupriavidus Species, Inquilinus limosus 
and Pandoraea species18. Some of these species have been associated with poor 
outcomes in CF, the role of some others was not clearly determined18.  
The increase in prevalence of MRSA seems less relevant in CF than in other patient 
populations, data from the American CF foundation patient registry showed that the 
prevalence of MRSA infection in CF has also increased from 6.1% in 2001 to about 
26.5% in 2011 (www.cff.org). Recently published studies demonstrated that the 
presence of MRSA in CF patients’ airways may worsen their clinical conditions and 
increase the frequency of antibiotic treatment they must undergo19,20,21 moreover, the 
drastic worsening of clinical conditions was demonstrated to lead to a reduced life 
expectancy20. Although MRSA chronic infections were recently recognized to be 
associated with poor survival and reduced lung function19,20, to date a clear 
guidance on how to manage these infections is still needed. A more accurate 
knowledge of local epidemiology, global epidemiology and antimicrobial resistance 
patterns would be helpful to this purpose. Few studies regarding MRSA 
characterization have been published concerning CF patients4,22. A thorough 
knowledge of the dissemination and molecular evolution of MRSA is required to 
develop effective strategies to prevent the spread of MRSA and MSSA strains in 
hospital settings. Data concerning molecular epidemiology and diffusion of Italian 
MRSA strains in CF are scanty. These patients are traditionally considered at risk 
for hospital-acquired infections due to their frequent hospitalizations and medical 
invasive treatment, but a recent study described a CA-MRSA prevalence4 higher 
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than US22. This Italian prospective study reported the presence and diffusion across 
the country of nine epidemic clones, whilst US data concerned particularly molecular 
typing of CA-MRSA, mainly represented by ST8-MRSA-IV. A well-delineated picture 
of MRSA global epidemiology would be helpful to set up therapeutic strategies and 
infection control measures. Data concerning molecular epidemiology of MRSA 
strains responsible for both first and chronic infections are still poor, so that the 
appropriateness of therapies remains unclear. To date lung transplantation is an 
established treatment option for patients with advanced CF, and is associated with 
improved quality of life and survival benefits. Severe pulmonary infections are 
characteristics of CF advanced disease stages, and the management of such 
infections is crucial for lung transplantation because the role that MRSA could play 
in these circumstances is still poorly investigated. 
 
Intensive care units (ICUs) and MRSA 
Recent studies demonstrated a continuing increase in MRSA hospital infections, 
probably reflecting the growing impact of medical interventions, devices, older age, 
and co-morbidities of patients23. The incidence of nosocomial infections in pediatric 
intensive care units (PICUs) due to use of mechanical ventilation, indwelling 
catheters and invasive monitoring is often higher than other wards. Rates of 
pneumonia are considerably higher among patients hospitalized in ICUs compared 
with those in hospital wards. Moreover, the risk of pneumonia is increased 3- to 10-
fold for the intubated patients receiving mechanical ventilation, as described since 
200224. Ventilator-associated pneumonia (VAP) is defined as a pneumonia occurring 
more than 48 hours after endotracheal intubation and initiation of mechanical 
ventilation. VAP usually shows mortality percentages from 24 to 50%, reaching 
higher values in specific settings24, and representing higher values comparing to 
urinary tract and skin infections. Appropriate antimicrobial treatment as well as rapid 
identification of infected patients represents important clinical goals. To this purpose, 
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clinical significance of MRSA colonization on hospital admission is still under 
debate. A recent US retrospective cohort study tracking patients for up to one year 
assessed that MRSA nasal colonization is a significant risk factor for future MRSA 
infection. The study showed that colonization with Panton-Valentine Leukocidin 
(PVL) positive MRSA is associated with a greater risk of developing MRSA 
infection25. Although MRSA screening at hospital admission seems to be promising, 
questions concerning the more effectiveness of universal versus targeted screening, 
as well as the more appropriate combination of body sites screening, are still waiting 
for an answer26,27. To date literature offers insufficient evidence to determine the 
consequences of universal screening or the effectiveness of other screening 
strategies26. A recent study comparing different body sites screening confirmed  that 
testing at least three of them (groin, nose and throat) allow to reach a higher 
sensitivity in detecting MRSA27.  Moreover, infection is often a cause of ICU 
admission, influencing both the clinical outcome of the patient and the 
microbiological environment of the ward28. Italian ICUs started in 2005 an 
observational, prospective, multicenter infection surveillance program. This project, 
named “Margherita”, allowed to collect data concerning ICU infections from all-over 
Italy. MDR microorganisms represented one of the most important problems 
concerning ICU-acquired infections, being MRSA on of the most represented MDR 
causing both VAPs and blood stream infections28. Molecular epidemiology of MRSA 
strains responsible for ICUs and PICUs infections is still a not really diffused tool, 
although a more delineate picture could represent a powerful tool to improve 
infection control measures and therapeutic schemes.  
 
SA, MRSA and virulence factors.  
SA strains may produce a large variety of toxins: cytolitic, including leukocidins, 
alpha-toxin and phenol-soluble modulins. Further important toxins are the SA 
superantigens, which include toxin shock syndrome toxin and lead to exacerbate 
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immune response by polyclonal T cell activation and massive cytokine release. SA 
also produces a wide range of toxins interfering with almost every mechanism of 
human innate host defense29. 
SA strains are known to cause three basic syndromes: skin abscesses and wound 
infections; deep-seated and systemic infections; toxemic syndromes such as toxic 
shock syndromes and staphylococcal scarlet fever,  staphylococcal scalded-skin 
syndrome, and staphylococcal food poisoning30. Pathogenesis of SA infections is a 
process based on two different stages. During the first stage, corresponding to the 
exponential phase of growth of in vitro cultures, adhesins and surface proteins are 
produced. The second stage corresponds to the post-exponential and stationary 
phases of growth in vitro, and is characterized by increased toxin production and 
consequent tissue damage and bacterial spread. This process has multifactorial 
molecular basis, depending on the expression of accessory gene products. In 
particular, accessory gene regulator (agr) locus controls the expression of most 
virulence factors. The agr quorum-sensing system represses the expression of 
surface proteins, including protein A (spa), and up-regulates the production of 
toxins, such as α-haemolysin and protease. The agr system is comprised of two 
divergent transcripts, RNAII and RNAIII. RNAII carries four genes, agrDBCA, which 
are dedicated to the synthesis, sensing, and processing of the quorum-sensing 
autoinducing peptide (AIP) required for the activation of the RNAII promoter. The 
divergent transcript RNAIII, activated in response to RNAII via AgrA, is a regulatory 
RNA molecule expressed maximally during the post-exponential phase and controls 
virulence gene expression at the transcriptional and translational levels, the latter via 
an antisense mechanism. A polymorphism in the aminoacid sequence of the auto-
inducing peptide and its receptor is the basis on which SA can be divided into four 
agr groups.  
Recent studies made it possible to establish a relationship between agr group and 
clinical onsets: group I and II strains are able to cause SE-mediated disease (food 
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poisoning),  group III strains are usually involved in toxic shock syndrome due to 
toxic shock syndrome toxin 1 (TSST-1), and group IV strains are generally involved 
in generalized exfoliative syndrome and bullous impetigo30. 
Immuno-evasion cluster (IEC) genes can be considered as virulence factors, since 
their presence appears to be related to escaping from immune system of the host. 
These genes are located on β-haemolysin-converting bacteriophages, and encode 
chemotaxis inhibitory protein of SA (CHIPS, encoded by chp), staphylococcal 
complement inhibitor (SCIN, encoded by scn), staphylokinase (SAK, encoded by 
sak) and enterotoxin A (SEA, encoded by sea gene), seven IEC variants have been 
identified basing on different combination of chp, scn, sak 31. All IEC variants carry 
SCIN, which represent an efficient complement inhibitor of the lectin, preventing 
opsonophagocytosis, killing by neutrophils and neutrophils chemotaxis. The role of 
IEC in both colonization and infection processes is still unclear, as well as 
characterization of this important genetic determinant.  
A further crucial element is PVL, a bipartite toxin with  pore-forming activity against 
human polymorphonuclear cells, monocytes and macrophages. Both SA and MRSA 
are able to produce it, and PVL-positive strains can be associated with foruncles 
and carbuncles, and/or community pneumonia with lung abscesses. The clinical 
sequelae of infections caused by PVL-positive strains tend to be more severe than 
PVL-negative SA. For example, pneumonia associated with PVL-positive SA is 
more frequently associated with sepsis, high fever, leucopenia, hemoptysis, pleural 
effusion and death32. Due to the relevance of clinical manifestations caused by PVL, 
the importance of a correct isolation and identification of producer strains is clear. 
Soft skin infections are currently poorly investigated, causing the loss of strains 
responsible for a dramatic underestimation of PVL producer strains, leading to a 
weak knowledge of diffusion and epidemiology PVL-positive strains.  
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Coagulase-negative staphylococci as a possible reservoir of virulence 
factors  
Coagulase-negative staphylococci (CoNS) comprise a multitude of species, many of 
which are opportunistic pathogens, being Staphylococcus epidermidis (SE) the most 
frequently encountered CoNS species on human skin and by far the most frequent 
source of infections among CoNS29. Pathogenicity of CoNS appears to stem from 
molecular determinants that evolved for commensal life on the skin, but may rise to 
additional use during infection29. Moreover, there are several recent findings 
indicating that SA acquired other factors that facilitate survival during infections from 
SE or other CoNS29. In some settings different staphylococcal species live in the 
same niches on human epithelial surfaces, being in close enough contact for genetic 
exchange to occur, probably due to horizontal gene transfer29. The arginine 
catabolic mobile element (ACME), a 31 kb mobile genetic element encoding an 
arginine deaminase (arc) and an oligopepetide permease (opp3), represents an 
important virulence factor for USA300 worldwide diffused CA-MRSA clone, and is 
commonly found in SE strains33. ACME seems to contribute to competitive fitness of 
USA300 with arc or opp gene clusters facilitating colonization or transmissibility 
capacity of USA300. To date, three different ACME types were described, diffusing 
among different clones. ACME type I, having both arc and opp, is associated with 
USA300. ACME type II, having arc only, was found in ST5 and ST59. ACME type III 
has the only opp gene29. Data concerning ACME presence in CoNS strains isolated 
in nosocomial settings are still scanty, limiting a correct epidemiology knowledge 
and avoiding real consideration of the importance of CoNS as a reservoir of 
virulence factors.  
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Aim of the study 
 
The picture emerging from recently published studies demonstrates that both 
MRSA, SA and CoNS epidemiology is rapidly changing: the prevalence of MRSA is 
increasing worldwide, and SE has become one of the major causes of indwelling 
devices infections. Moreover, MRSA epidemiology and genetic background are 
poorly described and characterized in high risk wards such as ICUs and CF 
patients, as well as the presence and characterization of genes encoding for 
virulence factors has also been poorly investigated, especially in pediatric patients. 
The aim of this study is to analyze molecular epidemiology and antimicrobial 
resistance of clinical MRSA strains, belonging to patients attending CF as well as 
PICU wards. Moreover, the presence of CoNS and their virulence factors would be 
investigated in PICU, to clarify the diffusion of such determinants. Molecular analysis 
of PVL-positive SA and MRSA strains represents another goal of this study, as well 
as their molecular characterization. This study should provide a detailed picture of 
molecular epidemiology and genetic background characterization of MRSA, SA and 
CoNS isolated in a third-level pediatric hospital, a useful tool to obtain a different 
point of view on infection control policies and therapeutic approaches. 
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Material and methods: 
Bacterial strains 
 Putative MSSA, MRSA, CoNS isolates will be obtained from Department of 
Pediatric Medicine wards (DPMW), PICUs and CF patients. Each sample collected 
during the hospitalization period was cultured for detection of MRSA isolates.  
 
Sample culturing and bacterial isolation. 
Samples were cultured inoculating plates of selective agar, the specific selective 
medium for SA (Mannitol Salt 2 Agar, bioMérieux, Marcy L’Etoile, France). 
Respiratory samples were mainly bronchial aspirates (BA) in the case of PICU 
patients, or sputum and swabs in case of CF patients. BA samples were treated 
after a quality control based on microscopic observation. Then, samples were 
processed following recommendations: 100 μl of samples were cultured on selective 
media plates, focusing attention in this specific case on the specific selective 
medium for SA (Mannitol Salt 2 Agar, bioMérieux, Marcy L’Etoile, France). Sputum 
samples from CF patients were usually cultured after incubation with dithiothreitol 
(1:1, volume to volume). 20 μl of samples were plated on seven different media, as 
recommended by consensus guidelines (www.SIFC.it).  After 48 hours of incubation 
in aerobic atmosphere at 37°C, plates were read in order to detect the presence of 
SA or CoNS. 
 
Biochemical identification 
Identification of putative SA isolates is based on typical colony morphology on 
selective culture media (Mannitol Salt 2 Agar, bioMérieux, Marcy L’Etoile, France). 
In order to confirm species-level identification, the Slidex Staph Plus (Bio-Rad) test 
was performed. This test is based on latex agglutination principle; latex particles 
have been sensitized with fibrinogen and IgG in order to detect clumping factor and 
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protein A, biochemical characteristics of SA. A positive reaction is evidenced by the 
formation of aggregates with the reagent test only, visible to the naked eye. CoNS 
are identified on the basis of the growth on  Mannitol Salt Agar, negative results of 
Slidex Staph Plus test, and Vitek GP cards (bioMérieux, Marcy L’Etoile, France). 
Methicillin resistance was initially tested using Oxa Screen Test Agar (Becton and 
Dickinson). Methicillin resistant strains are individuated until 2011 following CLSI 
instruction, and since 2012 EUCAST (www.eucast.org).  All MRSA, SA, CoNS 
strains were stored at -80°C. 
 
Antimicrobial susceptibility testing methods 
 Antibiotic susceptibility was evaluated assessing the activity of a large panel of 
drugs by means of the disk diffusion test on Mueller-Hinton agar (Kirby Bauer) until 
2011. This method is based on the diffusion of antibiotic into agar inoculated with a 
liquid culture of the isolate of interest. As soon as the antibiotic-impregnated disk 
comes into contact with the moist agar surface, water is absorbed into the filter 
paper and the antibiotic diffuses into the surrounding medium. The concentration 
immediately adjacent to the disk may exceed that in the disk itself. As the distance 
from the disk increases there is a logarithmic reduction in the antibiotic 
concentration. Simultaneous growth of bacteria occurs on the surface of the agar. 
When a critical cell mass of bacteria is reached, the inhibitory activity of the 
antibiotic is overcome and bacterial growth occurs. The interpretation criteria of the 
Kirby-Bauer test have been offered by different  international committees, such as 
the NCLSI or ESCMID’s EUCAST since 2011. The interpretative standards are 
derived from a correlation between zone sizes and minimum inhibitory 
concentrations (MICs) of those species that can be tested by disk diffusion method. 
The E-test (AB-Biodisc) were used in case of intermediate phenotypes to delineate 
glycopeptides resistance. A plastic strip calibrated with a MIC scale in μg/ml is laid in 
an agar plate streaked with the bacterial culture of interest. A predefined 
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concentration gradient of antibiotic agent, across 15 twofold dilutions of a 
conventional MIC method, is immobilized on the other surface of the carrier. After 
overnight incubation, the point at which the elliptical zone of growth inhibition 
intersects a quantitative scale on the strip determines the MIC.  
Since 2011, antimicrobial susceptibility tests were performed by means of Vitek 
(Vitek 2, bioMérieux, Marcy L’Etoile, France) using P580 cards and then P619; 
results were interpreted following CLSI and, since 2012, EUCAST criteria.  
Table 1 shows a comparison of antimicrobial agents used for Kirby-Bauer and then 
Vitek 2 method, interpretation rules changed as well.  
 
Table 1. Comparison of antimicrobial agents used for Kirby-Bauer and Vitek 2 
testing. 
Antimicrobial agent abbreviation Kirby-Bauer Vitek II (P580) 
Amoxicillin/ 
clavulanate 
AMC Yes NO 
Oxacillin OXA Yes Yes 
Cefoxitin FOX Yes Yes 
Cefaclor  CEC Yes NO 
Ceftazidim CAZ Yes NO 
Cefuroxime CXM Yes NO 
Tobramycin NN Yes Yes 
Gentamicin GM Yes Yes 
Erythromycin  E Yes Yes 
Ciprofloxacin CIP Yes NO 
Levofloxacin LVX Yes Yes 
Trimethoprim / Sulfamethoxazole SXT Yes Yes 
Rifampicin RA Yes Yes 
Vancomycin VA Yes Yes 
Teicoplanin TEC Yes Yes 
Doxycycline DO Yes NO 
Minocycline MNO Yes NO 
Clindamycin CLI Yes Yes 
Linezolid LZD Yes Yes 
Phosphomycin PHO NO Yes 
Fusidic Acid FUS NO Yes 
Moxifloxacin MOX NO Yes 
Mupirocin MUP NO Yes 
Tigecycline TIG NO Yes 
G Penicillin PEN NO Yes 
Tetracycline TET NO Yes 
Nitrofurantoin NIT NO Yes 
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DNA extraction: 
DNA extraction was performed according to manufacturer’s instructions using 
Nucleo Spin Tissue kit (Macherey-Nagel GmbH&Co. KG, Düren, Germany), with 
lysostaphin at 0.5 mg/ml for the lysis step.  
SCCmec typing: 
SCCmec typing of MRSA strains were done following the protocol published by 
Oliveira and de Lancastre in 200234, primers are listed in Table 2. A multiplex PCR 
mix was set up in a 50-μl volume, containing 1x PCR buffer, 200 μM (each) 
deoxynucleotide triphosphate (Roche Italia), 50 mM MgCl2; 400 nM concentrations 
of primers CIF2 F2, CIF2 R2, MECI P2, MECI P3, RIF5 F10, RIF5 R13; 800 nM 
concentrations of primers DCS F2, DCS R2, MECA P4, MECA P7; 200 nM 
concentrations of primers KDP F1, KDP R1, RIF4 F3, RIF4 R9; 1.25 U of AB Taq 
(AB Analitica, Italia) and 4 μl of template DNA. PCR amplifications were performed 
with the following parameters: 4 min at 94°C; 30 cycles of 94°C for 30 seconds, 
53°C fors 30 seconds and 72°C for 1 minute; 4 min at 72°C. PCR products were 
resolved in a 2% agarose gel in 1X TBE buffer at 100V and visualized after staining 
with GelRed Nucleic Acid Gel Stainer (Biotium, California). 
  
Table 2: list of primers for SCCmec typing34. 
Primer Oligonucleotide sequence(5’–3’) Amplicon 
size (bp) 
SCCmec 
type 
CIF2 F2 TTCGAGTTGCTGATGAAGAAGG 495 I 
CIF2 R2 ATTTACCACAAGGACTACCAGC 
KDP F1 AATCATCTGCCATTGGTGATGC 284 II 
KDP R1 CGAATGAAGTGAAAGAAAGTGG 
MECI P2 ATCAAGACTTGCATTCAGGC 209 II, III 
MECI P3 GCGGTTTCAATTCACTTGTC 
DCS F2 CATCCTATGATAGCTTGGTC 342 I, II, IV 
DCS R1 CTAAATCATAGCCATGACCG 
RIF4 F3 GTGATTGTTCGAGATATGTGG 243 III 
RIF4 R9 CGCTTTATCTGTATCTATCGC 
RIF5 F10 TTCTTAAGTACACGCTGAATCG 414 III 
RIF5 R13 GTCACAGTAATTCCATCAATGC 
MECA 
P4 
TCCAGATTACAACTTCACCAGG 162 Internal 
control 
MECA 
P7 
CCACTTCATATCTTGTAACG 
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The protocol published by Oliveira and colleagues in 2002 does not allow to detect 
SCCmec type V. To this purpose, primer list of another protocol proposed by Zhang 
and collaborators35 is shown in Table 3.  
 
Table 3. Primer list used in Zhang’s protocol 35. 
Primer Oligonucleotide sequence(5’–3’) Amplicon 
size (bp) 
SCCmec 
type 
 I-F GCTTTAAAGAGTGTCGTTACAGG 613 I 
 I-R GTTCTCTCATAGTATGACGTCC 
II-F CGTTGAAGATGATGAAGCG 398 II 
 II-R CGAAATCAATGGTTAATGGACC 
III-F CCATATTGTGTACGATGCG 280 III 
III-R CCTTAGTTGTCGTAACAGATCG 
IV a-F GCCTTATTCGAAGAAACCG 776 IV a 
IV a-R CTACTCTTCTGAAAAGCGTCG 
IV b-F TCTGGAATTACTTCAGCTGC 493 IV b 
IV b-R AAACAATATTGCTCTCCCTC 
IV c-F ACAATATTTGTATTATCGGAGAGC 200 IV c 
IV c-R TTGGTATGAGGTATTGCTGG 
IV d-F CTCAAAATACGGACCCCAATACA 881 IV d 
IV d-R TGCTCCAGTAATTGCTAAAG 
V-F GAACATTGTTACTTAAATGAGCG 325 V 
V-R TGAAAGTTGTACCCTTGACACC 
MecA147-
F 
GTGAAGATATACCAAGTGATT 147 Internal 
control 
MecA147-
R 
ATGCGCTAT AGA TTG AAA GGA T 
 
 Single target amplifications were performed in a 25 μl volume, containing 1x PCR 
buffer, 200 mM (each) deoxynulceotide (Roche, Italia), 50mM MgCl2, 1 U AB Taq 
(AB Analitica,Italia), and 0,2 μM of each primer. PCR conditions were as follow: 
94°C for five minutes, 30 cycles of 94°C for 1 minute, 50°C for 1 minute, 72°C for 2 
minutes, 72° for 10 minutes. PCR products were resolved in a 2% agarose gel in 1X 
TBE buffer at 100V and visualized after staining with GelRed Nucleic Acid Gel 
Stainer (Biotium, California). 
A further method was applied in SCCmec typing36, in order to detect different types 
basing on different region of the SCCmec mobile element. Table 4 shows the primer 
list, used at different concentrations in a master mix containing 1X PCR buffer; 1.5 
mM MgCl2; 40 μM (each) deoxynucleotide triphosphate (Roche, Italia); 0.2 μM 
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primers KDP F1, KDP R1; 0.4 μM primers CIF2 F2, CIF2 R2, RIF5 F10, RIF5 R13, 
SCCmec III J1F, SCCmec III J1R, SCCmec V J1F, SCCmec V J1R; 0.8 μM primers 
mecI  P2, mecI P3, DCS F2, DCS R1, mecA P4, mecA P7, ccrB2 F2, ccrB2 R2, 
ccrC F2, ccrC R2; 1.25 U of AB Taq (AB Analitica, Italia) and 2 μl of DNA. The 
optimal cycling conditions were the following: 94°C for 4 minutes, 30 cycles of 94°C 
for 30 seconds, 53°C for 30 seconds and 72°C for 1 minute and a final extension at 
72°C for 4 minutes.  
 
Table 4. Primer used following the protocol by Mileiriço and colleagues36.  
Primer Oligonucleotide sequence(5’–3’) Amplicon 
size (bp) 
SCCmec 
type 
CIF2 F2 TTCGAGTTGCTGATGAAGAAGG 495 I, J1 
region CIF2 R2 ATTTACCACAAGGACTACCAGC 
ccrC F2 GTACTCGTTACAATGTTTGG 449 V, ccr 
complex ccrC R2 ATAATGGCTTCATGCTTACC 
RIF5 F10 TTCTTAAGTACACGCTGAATCG 414 III, J3 
region RIF5 R13 ATGGAGATGAATTACAAGGG 
SCCmec 
V J1 F 
TTCTCCATTCTTGTTCATCC 377 V, J1 
region 
SCCmec 
V J1 R 
AGAGACTACTGACTTAAGTGG 
dcs F2 CATCCTATGATAGCTTGGTC 342 I, II, IV, 
VI, J3 
region 
dcs R1 CTAAATCATAGCCATGACCG 
ccrB2 F2 AGTTTCTCAGAATTCGAACG 311 II, IV, ccr 
complex ccrB2 R2 CCGATATAGAAWGGGTTAGC 
kdp F1 AATCATCTGCCATTGGTGATGC 284 II, J1 
region kdp R1 CGAATGAAGTGAAAGAAAGTGG 
SCCmec 
III J1 F 
CATTTGTGAAACACAGTACG 243 III, J1 
region 
SCCmec 
III J1 R 
GTTATTGAGACTCCTAAAGC 
mecI P2 ATCAAGACTTGCATTCAGGC 209 II, III mec 
complex mecI P3 GCGGTTTCAATTCACTTGTC 
mecA P4 TCCAGATTACAACTTCACCAGG 162 Internal 
positive 
control 
mecA P7 CCACTTCATATCTTGTAACG 
 
PCR products were resolved in a 3% agarose gel in 1XTris-Borate-EDTA buffer, at 
100V and were visualized after staining with GelRed Nucleic Acid Gel Stainer 
(Biotium, California).  
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spa typing: 
The sequence of the polymorphic region X of the SA protein A (spa) locus has been 
used to developed a single-locus sequence typing technique for MRSA37. The spa 
locus consists of a number of mainly 24-bp repeats, and its diversity is attributed to 
deletions and duplications of the repeats, and due to point mutations. PCR 
amplification of a portion of spa gene was performed in a 25 μl volume, containing 
1X PCR Buffer, 50 mM MgCl2,350 mM total deoxynucleotide (Roche, Italia), 0.5 mM 
PA 1095F forward primer (5’-AGACGATCCTTCGGTGAGC-3’) and PA 1517R 
reverse primer (5’-GCTTTTGCAATGTCATTTACTG-3’), 2.5 U of AmpliTaq Gold 
DNA polymerase (Applied Biosystems) and 2 μl of chromosomal DNA. Thermal 
cycling parameters included an initial 10 minutes at 95°C; 30 cycles of 30 seconds 
at 95°C, 30 seconds at 60°C, 45 seconds at 72°C; 72°C for 10 minutes. PCR 
products were resolved in a 1% agarose gel in 1X TBE buffer at 100V and 
visualized after staining with GelRed Nucleic Acid Gel Stainer (Biotium, California). 
Spa types were assigned using a free web-application named spa typer finder 
(http://spatyper.fortinbras.us/). 
 
MLST 
PCR partial amplification of the seven house-keeping genes was performed 
following protocol by Enright and colleagues38. Table 5 presents the primer list.  
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Table 5. Primer list for MLST analysis.  
Primer Oligonucleotide sequence(5’–3’) 
arcC UP TTGATTCACCAGCGCGTATTGTC 
arc DN AGGTATCTGCTTCAATCAGCG 
aroE UP ATCGGAAATCCTATTTCACATTC 
aroE DN GGTGTTGTATTAATAACGATATC 
glpF UP CTAGGAACTGCAATCTTAATCC 
glpF DN TGGTAAAATCGCATGTCCAATTC 
gmk UP ATCGTTTTATCGGGACCATC 
gmk DN TCATTAACTACAACGTAATCGTA 
ptA UP GTTAAAATCGTATTACCTGAAGG 
ptA DN GACCCTTTTGTTGAAAAGCTTAA 
tpI UP TCGTTCATTCTGAACGTCGTGAA 
tpI DN TTTGCACCTTCTAACAATTGTAC 
yqiL UP CAGCATACAGGACACCTATTGGC 
yqiL DN CGTTGAGGAATCGATACTGGAAC 
 
PCRs were carried out in a 25-μl reaction volumes containing 2 μl of chromosomal 
DNA, 1X PCR buffer, 50 mM MgCl2, 0.10 μM of each primer, 200 mM (each) 
deoxynucleotide (Roche, Italia), 1 U of AB Taq DNA polymerase (AB Analitica, 
Italia). Thermal cycling parameters included an initial 5-minutes denaturation at 
95°C, followed by 30 cycles of annealing at 55°C for 1 min, extension at 72°C for 1 
min, followed by a final extension time of 5 minutes at 72°C. PCR products were 
resolved in a 1% agarose gel in 1X TBE buffer at 100V and visualized after staining 
with GelRed Nucleic Acid Gel Stainer (Biotium, California). Sequence types (STs) 
were attributed submitting the DNA sequences obtained to the online MLST 
database (http://www.mlst.net/). 
 
DNA sequencing  
PCR products were purified by means of ExoSAP-IT (Affymetrics USB, Santa Clara, 
CA), following manufacturer’s recommendations. 5 μl of PCR product were mixed 
with 2 μl of ExoSAP-IT, and then incubated at 37°C for 15 minutes. The enzyme 
combination was inactivated incubating it at 80°C  for 15 minutes.  
Nucleotide sequencing  reactions were set up using Big Dye Terminator v. 3.1 Cycle 
Sequencing chemistry (Applied Biosystems, Life Technologies) on 310 Genetic 
Analyzer (Applied Biosystems, Life Technologies). Sequencing products were 
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analyzed using the free software BioEdit, Biological sequence alignment editor 
(copyright by Tom Hall, Ibis Bioscience, CA).  
Phylogenetic trees were obtained using the free software MEGA6 39, following 
recommendations by Hall40.  
 
ACME 
The molecular characterization of ACME was performed according to previously 
described methods (Ellington MJ, 2008). Reactions were set up in a 25-μl volume 
using 1X PCR Buffer, 0.1 μM of each primer, 3 mM MgCl2, 200 μM of each 
deoxynucleotide (Roche, Italia), 1 U of AB Taq (AB Analitica), and 2 μl of 
chromosomal DNA.  
Optimal cycling conditions were the following: 5 minutes at 95°C, 30 cycles of 95°C 
for 1 minute, 50°C for 1 minute and 72°C for 2 minutes, followed by 72°C for 5 
minutes. PCR products were resolved in a 1% agarose gel in 1X TBE buffer at 100V 
and visualized after staining with GelRed Nucleic Acid Gel Stainer (Biotium, 
California). 
 
Toxin genes testing 
PCR to detect PVL genes was set up as previously described by Lina and 
colleagues 41, using primers luk-PV1 (5’ -
ATCATTAGGTAAAATGTCTGGACATGATCCA-3’) and luk-PV2 (5’-
GCATCAASTGTATTGGATAGCAAAAGC-3’). Thermal cycling conditions were the 
following: 30 cycles of 94°C for 30 seconds, 55°C for 30 seconds, 72°C for 1 minute. 
PCR products were resolved by electrophoresis through 1.5% agarose gel, and 
analyzed after GelRed Nucleic Acid Gel Stainer (Biotium, California) staining. 
Nucleotide sequences of PCR products were determined to confirm PCR specificity, 
and to set up diagrams.  
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The agr typing was performed as previously described by Shopsin and colleagues in 
200342. Table 6 shows the primer list: one forward primer named pan-agr was used 
in combination with four different reverse primers to detect agr types basing on 
different sizes of PCR products.  
 
Table 6. List of primers used for agr typing. 
Primer Oligonucleotide sequence(5’–3’) Amplicon 
size (bp) 
pan-
agr 
ATGCACATGGTGCACATGC - 
agr I GTC ACAAGTACTATAAGCTGCGAT 440 
agr II GTATTACTAATTGAAAAGTGCCATAGC 572 
agr III CTGTTGAAAAAGTCAACTAAAAG CTC 406 
agr IV CGATAATGCCG TAATAC CCG 588 
 
PCR was performed in a 25-μl volume mixture, containing 2 μl of chromosomal 
DNA, 2 mM MgCl2, 0.1 μM of each primer, 350 μM (total) deoxynucleoside (Roche, 
Italia), 2.5 U of AB Taq (AB Analitica). Thermal cycling was performed following 
these conditions: 25 cycles consisting of 1 minute at 94°C, 1 minute at 55°C, 1 
minute at 72°C. PCR products were resolved on a 1% agarose gel, and detected 
after GelRed Nucleic Acid Gel Stainer (Biotium, California) staining.  
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Results: 
 
Strains collection: 
Clinical strains were collected until the last day of 2012, with the exception of DPMW 
samples sent to search PVL-producers isolates, collected until the last day of 2013. 
Table 7 resumes sample collection and MRSA and MRCoNS obtained sampling 
PICU and CF patients.  
 
Table 7. MRSA and MRCoNS collected during the study period in PICU and CF 
wards.  
Ward Year Sample or 
patients  
MRSA 
(%) 
MRCoNS 
(%) 
PICU 
 
2010 202 25 
(11.4%) 
15 
(7.5%) 
2011 210 29 
(12.8%) 
31 
(14.7%) 
2012 180 10 
(5.5%) 
16 
(9%) 
 
CF 
2010 283 28 
(9.9%)* 
- 
2011 301 26 
(8.6%)* 
- 
2012 285 33 
(11.5%)* 
- 
* MRSA percentage referred to patients’ number instead of samples. 
MRSA: meticillin-resistant Staphylococcus aureus; 
MRCoNS: meticillin-resistant coagulase-negative staphylococci. 
 
 
During routine clinical sampling, MRSA and MRCoNS were isolated from PICU 
samples. Due to the lack of data concerning MRSA and MRCoNS molecular 
epidemiology of Italian PICU patients, more than one strain/patient were collected 
and analyzed in order to obtain a more delineated epidemiological PICU picture and 
more information concerning long-term patients. Considering that CF patients are 
microbiologically monitored every three months, one strain/year/patient was 
collected and analyzed. Forty-nine patients supplied all the analyzed strains.   
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Clinical suspects of both soft tissue and invasive infections led to collect several 
samples, as described in Table 8.  
 
Table 8. Collected samples and PVL-positive ones.  
Year   Total number 
of samples 
PVL- positive 
samples 
2011 10 4 
2012 50 9 
2013 52 17 
 
During this period of time, it was possible to collect PVL-positive staphylococcal 
isolates belonging to Pediatric patients as well as their sibling or parents, and all 
these strains were analyzed.  
Each antimicrobial susceptibility testing result was considered to build up a more 
accurate picture, but molecular analysis were performed on a selected number of 
strains, as shown in Table 9. 
 
Table 9. Strains belonging to PICU and CF patients undergoing to molecular 
characterization.  
Ward Year Number of 
MRSA 
strains 
Selected 
MRSA 
strains 
PICU 2010 25 17 
2011 29 11 
2012 10 6 
CF 2010 28 27 
2011 27 27 
2012 33 29 
 
PICU patients were admitted with different diagnosis, 15 out of 23 (65%) underwent 
a tracheotomy before the admittance. Five out of 23 patients (21%) were 
progressively monitored  during the study period. Table 10 shows characteristics of 
PICU patients.  
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Table 10. Main characteristics of PICU patients.  
Ward Year MRSA 
positive 
patients 
Median age 
(range, 
years) 
Number of 
Tracheotomy 
positive 
PICU 2010 12 2.44 years 
(0.8-17) 
6 
2011 12 1.88 years 
(0.08-7) 
8 
2012 6 2.83 years 
(1-5) 
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CF patients showed different characteristics, as shown in Table 11, in particular 
adult patients also attend to CF Center of Florence. MRSA strains belonging to adult 
patients were included since they attend to the Center, being subject to follow-up in 
a Pediatric hospital.   
 
Table 11. Description of CF patients.  
Ward Year Patients Median 
age 
(range) 
Number of 
First 
infections 
Number of 
Chronic 
infections 
CF 2010 28 19.5 
(0.4-49) 
6 22 
2011 27 20.3 
(5-40) 
6 21 
2012 33 17.6 
(0.8-48) 
14 19 
 
A chronic infection is defined as “When more than 50% of months, when samples 
had been taken, were MRSA culture positive”. Patients having no growth of MRSA 
during the previous twelve months, but having previously been MRSA culture 
positive were defined free of infection. These definitions were chosen according to 
Leeds criteria used to define patients chronically infected by Pseudomonas 
aeruginosa 43 due to the lack of an universally accepted definition of chronic MRSA 
infection.  
As shown in Table 12, PVL-positive strains collection started in 2011 since this 
problem emerged in that period, being necessary to set-up molecular approaches to 
determine the presence of such isolates in selected cases. 
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Table 12. Characteristics of patients infected by PVL-positive strains.  
Year PVL-
positive 
strains 
MRSA 
strains 
SA strains 
2011 4 0 4 
2012 10 6 4 
2013 13 2 11 
 
 
Antimicrobial susceptibility testing results 
Technological progresses, such as automated systems utilization, had a strong 
impact on collected data, leading to use extreme carefulness in interpretation. The 
number of comparable antimicrobial agents became smaller, as shown in Table 1 of 
Materials and Methods Section, and some change occurred during the study period. 
Figure 1 compares data concerning antimicrobial resistance during this three-year 
study.  
 
 
Figure 1. Comparison of antimicrobial resistance patterns of CF and PICU MRSA isolates. 
E: Erythromycin; CM: Clindamycin; LVX: Levofloxacin; TM: Tobramycin; GM: Gentamicin; 
SXT: Trimethoprim / Sulfamethoxazole; RA:Rifampicin;Va: Vancomycin; TEC: teicoplanin; 
LZD: linezolid. 
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Statistical comparisons are unfortunately not suitable due to different methods and 
interpretation rules, progressively changed during the project time, as reported in 
Materials and Methods section.  
Resistance to glycopeptide and linezolid was not detected, whereas other 
antimicrobial agents showed high percentages of resistance. Resistance level 
appear to be comparable in PICU and CF patients, although differences are 
detectable. A higher percentage of CF strains showed resistance to thimetoprim-
sulfomethoxazole and rifampin, whilst comparable values of resistance against 
erythromycin, tobramycin, gentamicin were showed with difference during the years. 
PICU strains appeared to be more resistant against levofloxacin, and showed higher 
resistance percentages during 2011, suggesting the diffusion of particularly resistant 
strains.  
If we get a look on singular wards, we can see how resistance modified through 
these three years. Figure 2 shows CF wards.  
 
 
Figure 2. Changing MRSA antimicrobial resistance in CF ward, from 2010 to 2012. 
E: Erythromycin; CM: Clindamycin; LVX: Levofloxacin; TM: Tobramycin; GM: Gentamicin; 
SXT: Trimethoprim / Sulfamethoxazole; RA:Rifampicin;Va: Vancomycin; TEC: teicoplanin; 
LZD: linezolid. 
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It is interesting to note that percentage of resistance against levofloxacin, 
tobramycin, gentamycin, trimethoprim-sulfomethoxazole and rifampin changed in 
2012. The statistical valence of such differences are unfortunately not definable,  
and may be referred to the use of automated methods and changes in expert rules 
and interpretation standards. 
In Figure 3 are showed PICU percentage of resistance against antimicrobial agents. 
 
 
Figure 3. Antimicrobial resistance percentages of MRSA isolates in PICU.  
E: Erythromycin; CM: Clindamycin; LVX: Levofloxacin; TM: Tobramycin; GM: Gentamicin; 
SXT: Trimethoprim / Sulfamethoxazole; RA:Rifampicin;Va: Vancomycin; TEC: teicoplanin; 
LZD: linezolid. 
 
There is no resistant strain against glycopeptides, but differences comparing each 
year are notable concerning other antimicrobial agents. During 2010 23 MRSA 
strains were collected from specimens belonging to 13 patients; in 2011 29 strains 
came from 16 different patients; during 2012 10 strains were collected from 9 
patients. A total of 31 patients supplied 62 strains from 2010 to 2012. Five out of 31 
patients supplied strains for more than one year, three out of five showed infection in 
two different years, and the remaining two patients covered the entire study period. 
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These circumstances may have given a contribution to differences, the statistical 
valence of which could not be determined.  
Methicillin-resistant ConS (MRCoNS) were detected and collected from specimens 
belonging to PICU patients. Figure 4 shows the comparison of antimicrobial 
resistance percentage of MRSA and MRCoNS.  
 
 
Figure 4: Comparison of antimicrobial resistance between MRSA and MRCoNS 
from PICU patients. 
E: Erythromycin; CM: Clindamycin; LVX: Levofloxacin; TM: Tobramycin; GM: Gentamicin; 
SXT: Trimethoprim / Sulfamethoxazole; RA:Rifampicin;Va: Vancomycin; TEC: teicoplanin; 
LZD: linezolid. 
 
 
MRCoNS represent an important reservoir of resistance genetic determinants as 
well as SCCmec elements. MRCoNS show an higher percentage of resistant 
strains, but it should be taken into account that more than one strain/year/patients 
was chosen, determining a possible influence on data. Statistical analysis can’t be 
performed due to the different antimicrobial susceptibility testing methods as well as 
changing in interpretation rules.  
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Molecular characterization of collected isolates 
A thorough knowledge of the dissemination and molecular evolution of MRSA are 
required to develop effective strategies to prevent the spread of such strains. 
Therefore, various molecular typing techniques have been developed. In general, 
there are “band-based” and “sequence-based” methods to determine the genetic 
background of SA and MRSA, but “sequence-based” methods are preferred 
because the data are exchangeable. The most commonly used typing methods are 
pulsed-field gel electrophoresis (PFGE), MLST, spa typing, and SCCmec typing. 
Although PFGE is still regarded by many authors as a gold standard for 
benchmarking new typing methods, sequence-based typing methods generate 
unambiguous and portable data, easily comparable in different laboratories of 
different countries. Moreover, due to their important role in virulence and 
pathogenicity of MRSA strains, molecular characterization of toxins such as PVL  is 
definitely a relevant issue. 
 
SCCmec typing 
All the available methods for SCCmec typing are based on different structural 
properties of this genetic element, but a single universal method for its classification 
is still needed. A number of methods have been developed to investigate the 
structure of SCCmec34,35,36. Multiplex PCR assays are available to discriminate 
among SCCmec type I to IV34, in which mecA and different loci on SCCmec are 
detected, as well as type I to V35. 
Three different methods were applied to properly discriminate among SCCmec 
types from I to VI36; since others SCCmec types occurred rarely, further methods 
are going to be set up in the next future. Table 13 illustrated the distribution of 
different SCCmec types in PICU and CF wards during the study period. 
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Table 13. SCCmec typing of collected strains.   
Ward SCCmec 
type I 
SCCmec 
type II 
SCCmec 
type III 
SCCmec 
type IV 
SCCmec 
type V 
Not 
determined 
PICU_2010 7 0 0 5 5 0 
PICU_2011 7 0 1 2 1 0 
PICU_2012 6 0 0 0 0 0 
CF_2010 14 1 3 6 2 1 
CF_2011 13 1 3 4 3 1 
CF_2012 11 2 4 4 5 3 
 
Only two strains did not result to belong to a known SCCmec type,  being necessary 
to test the less frequently noted chromosomal cassettes mec. 
SCCmec typing of CoNS strains showed the presence of 8 out of 27 (30%) SCCmec 
type I, 1 (4%) SCCmec type II, 6 (22%) SCCmec type III, as well as type IV and not 
determined.  
Nine out of 30 (30%) collected PVL-producer strains were MRSA, being the 
remaining 21 SA. All MRSA strains belonged to SCCmec type IV, and SA strains did 
not harbor SCCmec element. 
 
Spa typing results 
This analysis is a  single-locus sequence typing based on the polymorphic region X 
of the S. aureus protein A (spa)37. This locus consist of repeats of 24 base-pair and 
its diversity is attributed to deletions and duplications of the repeat due to point 
mutations. This method can be used successfully to investigate both molecular 
evolution and hospital outbreaks of MRSA.  
This analysis was carried out on all the 147 collected strains, and results were 
obtained for 30 isolates due to the use of a  public database. One of the most 
represented type was t2167, followed by t127 as well as t002 and t008. 
 Performing spa typing was possible to assess strain sharing as well as the 
presence of a particular type indicating a LA-MRSA. This spa type, t127, was shared 
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by three CF patients: two siblings and another patient. MLST analysis was the 
necessary further step to properly characterize collected strains.  
 
MLST analysis results 
Basing on the nucleotide sequences of seven different housekeeping genes, it is 
possible to assign a sequence type (ST): isolates are defined by the alleles present 
at the seven loci (the allelic profile), and each unique allelic profile is assigned an 
ST38. Isolates with the same ST, therefore, have identical sequences at all seven 
MLST loci and are considered to be members of a single clone. Data analysis allows 
to provide an evolutionary picture of isolates collection compared to already known 
strains. MLST is an excellent tool to investigate the evolution of MRSA: a nucleotide 
sequence-based approach for the unambiguous characterization of bacterial 
isolates and other organisms. The aim of MLST is to provide a portable, accurate, 
and highly discriminating typing system. This approach allows a comparison of 
results with global epidemiology data, assessing worldwide strain diffusion.  
MLST profiles of 102 MRSA and SA strains were obtained. PICU predominant clone 
appeared to be ST128-MRSA-I, and epidemic clone named Southern Germany 
clone. This particular clone was shared by four patients in 2010, 2011, and 2012. 
The other representative clone emerged during this study was ST22-MRSA-IV, an 
already described CA-MRSA clone.  
CF patients showed the presence of different clones. Eight out of 49 patients were 
infected by strains belonging to Southern Germany clone, 4 to ST5-MRSA-I, 3 to 
ST8-MRSA-IV, one to ST45-MRSA-IV or Berlin clone. One patient harbored ST239-
MRSA-III or Brazilian-Hungarian clone, two patients ST1-MRSA-III. Two patients 
shared ST152-MRSA with undetermined SCCmec, and the USA300 variant 
represented by ST8-MRSA-V. Moreover, ST398 (traditionally a LA-MRSA) was 
found in two different patient, one of which harbored SCCmec type V.  
33 
 
15 out of 30 PVL-positive strains were genotyped by means of MLST, showing the 
presence of epidemic lineages such as USA300, ST5-MRSA-IV or Pediatric clone, 
and ST30-MRSA-IV or Southwest Pacific clone (SWP).  
 
Virulence factors characterization 
Several virulence factors were tested, to obtain a more accurate characterization of 
collected strains.  
 
ACME typing results 
ACME is a novel genetic element able to confer an enhanced ability to grow and 
survive within the host29. This genomic island appears to have been transferred into 
USA300 from Staphylococcus epidermidis. Strains able to acquire this genetic 
element belong to USA300. ACME contains two gene clusters (arc encoding a 
secondary arginine deiminase system and opp-3 encoding an ABC transporter) that 
are homologous of virulence determinants in other bacterial species, highlighting 
their importance.  
Two MRSA-IV strains belonging to PICU and 10 belonging to CF patients were 
tested for ACME presence. Nineteen CoNS isolates were tested. None of the PICU 
tested strain was positive for ACME. Only two CF strains belonging to the same 
patient chronically infected tested positive for ACME type I. CoNS showed a higher 
grade of variety: 7 out of 27 strains belonged to type I, 3 to type II and the last one 
was a type III; the remaining strains tested negative for ACME.  
 
agr typing results 
This locus controls the expression of most virulence factors. The agr quorum-
sensing system represses the expression of surface proteins, including spa and 
upregulates the production of toxins, such as α-hemolysin and protease. The agr 
system is comprised of two divergent transcripts, RNAII and RNAIII. RNAII carries 
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four genes, agrDBCA, which are dedicated to the synthesis, sensing, and 
processing of the quorum-sensing autoinducing peptide (AIP) required for the 
activation of the RNAII promoter. The divergent transcript RNAIII, activated in 
response to RNAII via AgrA, is a regulatory RNA molecule expressed maximally 
during the post-exponential phase and controls virulence gene expression at the 
transcriptional and translational levels, the latter via an antisense mechanism. A 
polymorphism in the aminoacid sequence of an auto-inducing peptide and its 
receptor is the basis on which SA can be divided into four groups.  
All collected strains were tested for agr grouping; Table 14 illustrates the distribution 
of types among the collected strains.  
 
Table 14. Distribution of agr types among the collected isolates.  
Ward Number 
of agr 
type I 
 
Number 
of agr 
type II 
Number 
of agr 
type III 
Number 
of agr 
type IV 
PICU_2010 6 2 1 6 
PICU_2011 2 1 0 3 
PICU_2012 4 1 1 0 
CF_2010 11 0 2 6 
CF_2011 7 0 4 8 
CF_2012 6 0 5 6 
 
Association between agr and clinical manifestations were demonstrated30, as well as 
with nasal colonization44. Data concerning both chronic and first infections are still 
scanty, so that it’s difficult to highlight eventual correlation between infection and agr 
type. 
 
IEC typing results 
Eleven PICU and 41 CF MRSA strains were tested for IEC typing. PICU strains 
were type A (4 out of 11), and B (one strain). Five strains tested positive for some 
IEC genes: chp, sak, sea, hlb. 40 CF strains were tested for IEC presence, 5 of 
which belonged to type A, 2 to type B, 10 to type D, 3 to type E, 3 to type F, and 10 
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tested positive for only some genes. At this stage, it is impossible to highlight a 
correlation between chronic or first infection in CF patients and IEC, or to compare 
IEC types of MRSA belonging to patients attending to these two wards.  
 
PVL testing results 
PVL is one of the major virulence factors characterizing SA and MRSA. Due to the 
importance of the clinical manifestations caused by PVL, a correct isolation and 
identification of producer strains appear to be crucial. Soft skin infections are 
currently poorly investigated, causing the loss of strains responsible for a dramatic 
underestimation of PVL producer strains, leading to a weak knowledge of diffusion 
and epidemiology PVL-positive strains. Basing on clinical symptoms, 30 PVL-
positive SA and MRSA strains were collected from DPMW during the study period. 
Moreover, PVL presence was tested on 25 out of 34 PICU strains, and 38 out of 83 
CF strains. All PICU strains tested negative, whilst one CF strain tested positive. 
PVL gene partial sequencing was performed, and this 500 bp portion allowed to set-
up a diagram describing differences between DPMW and the CF strain, as shown in 
Figure 5.  
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Figure 5. Diagram of partial PVL sequences, and a reference sequence 
(gi|156153054|.).  
ST: soft tissue infection; INV: invasive infection; TL: sample from lesion; TN: nasal swab.  
 
 
FI59_12 represents the isolate belonging to CF patient, chronically infected by 
MRSA since 2006. One MRSA strain/year was tested for PVL, highlighting the 
presence of PVL genes in all these isolates. PVL partial sequences were used to 
built another diagram to examine if some changes occurred, as shown in Figure 6.  
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Figure 6. Diagram of PVL partial sequences belonging to a CF patient, and of the 
reference sequence gi|156153054|. 
 
 
Partial PVL sequences of CF isolates appeared to be really conserved, according to 
the presence of a chronic infection. This may be the first report of a chronic infection 
sustained by a PVL-positive MRSA strain. Evolutionary analysis was set up with 
standard parameters following a recently published protocol40 with bootstrap test. 
These data should not be taken into account for a phylogenic study due to their 
high-grade of similarity and, thus, conservation. Despite that, Figure 5 and 6 are 
suitable to illustrate that PVL partial sequencing are strongly conserved, being the 
more divergent sequence the one belonging to CF strain responsible for pulmonary 
infection. Moreover, this particular sequence appears to be highly conserved since 
2006. 
Molecular typing of both SA and MRSA PVL-positive strains gave interesting results. 
MRSA strains belonged to SWP ST30-MRSA-IV, and infected a family recently 
immigrated from Brazil. Two patients, a mother with recurrent soft tissue infections 
and her six-years old daughter, shared ST8-MRSA-IV clone. A 15 years-old boy had 
a trip in Venezuela and came back with a soft-tissue infection due to ST22-MRSA-IV 
or UK EMRSA-15. A one-year old boy reported an infection caused by ST5-MRSA-
IV or Pediatric clone.  
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Chronic MRSA infection in ICU 
This three-year survey allowed to monitor chronically infected patient, and to 
highlight the presence of epidemic lineages in ICU. Three patients were monitored 
during the entire study period, being positive for the presence of the same strain. 
One patient was infected by Southern Germany clone, another by ST22-MRSA-IV, 
and the last one maintained the strain, which was characterized by an unknown 
genotype.  
 
First MRSA infection in CF patients 
Since early eradication therapy for MRSA is still under debate17, data concerning 
first infection are really important. In particular, determining if particular clones are 
cleared or able to establish a chronic infection should have a great relevance. 
Twenty-five strains responsible for first infection in CF patients were collected: 13 
belonged to HA-MRSA, and 12 to CA-MRSA. CF patients were believed to have 
exposure to HA-MRSA more than CA-MRSA infection due to the clinical practices 
they usually undergo, but in this case the two groups are almost equal. Median age 
of patients infected by HA-MRSA is 21.3 years (range 2-49), CA-MRSA infected 
patients showed a median age of 13.9 years (range 0.4-35). This difference is not 
quite statistically significant (t-test, p 0.0830). 
To date, five first infections became chronic: one CA-MRSA, three HA-MRSA, and a 
LA-MRSA infection. All but two of these strains belonged to epidemic lineages: 
Southern Germany clone, ST152-MRSA with undetermined SCCmec, ST398-
MRSA-V. Basing on these data, the possibility that the establishment of a chronic 
infection could depend on the better fitness characterizing epidemic clones appear 
to be more likely than other hypothesis.  
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Chronic infection and CF patients 
Chronic MRSA infection in CF patients was demonstrated to have serious influence 
on survival20. Fourteen patients were chronically infected by MRSA at the time of the 
study. It was possible to characterize MRSA strains belonging to ten out of 14 
chronically infected patients from first colonization until 2012. Figure 7 summarizes 
chronic patients monitored since first infection: there was only one strain 
replacement, and each infection is caused by a known epidemic clone.  
 
 
 Figure 7. From first to chronic infection. 
 
In one case only first infection strain was replaced after two years by a known 
epidemic clone establishing another chronic infection. In general, epidemic lineages 
are rarely cleared or replaced by another strain.  
Two cases of siblings are part of chronically infected patients. The first two were 
adult, and shared Southern Germany clone until one of them died after a respiratory 
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failure. The other two are younger and still sharing a MRSA strain characterized by 
spa type 127, associated with LA-MRSA.  
 
CF patients and lung transplantation 
Lung transplantation represents a therapeutic option for the end stage of pulmonary 
disease. Patients undergoing this clinical practice are usually infected by MDR 
strains including mucoid Pseudomonas aeruginosa, other Gram-negative rods and 
molds such as Aspergillus species. MRSA is a part of this plethora of pathogens, 
and its effective role in pathogenic process is difficult to determine. Twelve CF 
patients who underwent lung transplantation were analyzed, 8 males and 4 females, 
median age 30.8 years (range 20-43 years-old). The chosen follow-up period started 
in 1984 and ended in 2012, allowing to monitor the presence of pathogens before 
and after lung transplantation. 958 culture tests results before and after lung 
transplantation were examined, showing the presence of several different pathogens 
as shown in Figure 8.   
 
Figure 8: Pathogens recovered in respiratory samples of CF patients before 
and after lung transplantation.  
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Five out of 12 patients were chronically colonized by MRSA and Gram-negative 
species before lung transplantation, as shown in Figure 9.  
 
 
Figure 9: Chronic infection before and after lung transplantation. 
 
 
MRSA strains infecting patients undergoing lung transplantation belonged to ST128-
MRSA-I or Southern Germany clone, ST5-MRSA-I or UK EMRSA-3, ST8-MRSA-IV. 
All MRSA strains were cleared after lung transplantation, since patient FI13 showed 
MRSA before and after lung transplantation, but the genotypes of such strains were 
different, suggesting a replacement. Gram-negative rods such as Pseudomonas 
aeruginosa and Inquilinus limosus were maintained.  
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Discussion 
 
Since its discovery, SA represented a serious threat for public health due to its great 
capacity to develop antimicrobial resistance in a short period of time. Four different 
waves of resistance were recently described by Chambers1. Wave 1 started after 
penicillin introduction, and was caused by a PVL-producer strain. Wave 2 was 
started by Archaic clone (ST250-MRSA-I) after the introduction of methicillin into 
clinical practice. Wave 3 began in 1970s in healthcare settings, and was caused by 
MRSA harboring the novel SCCmec types II and III. Vancomycin usage for 
treatment of such infections led to emergence of VISA strains. Wave 4, started in 
1990s, marked the emergence of CA-MRSA1.  
Unfortunately the present study was set up and started just before VITEK acquisition 
and EUCAST venue, becoming impossible to properly compare data obtained in 
2010, 2011 and 2012 with the exception of the lack of resistance to glycopeptides or 
linezolid. A recent study, dating from 2012, compared EUCAST and CLSI and their 
different effects on rods responsible for acute infection, stating that minor 
discrepancies occurred between the two methods45. In spite of that study, the choice 
to compare antimicrobial susceptibility tests obtained by means of manual 
techniques and automated methods appear inappropriate, thus these results 
represents only a description.  
SA and MRSA infections represent a global public health issue even due to the high 
cost of management. MRSA infections cause societal costs such as expenses 
caused by extension of hospital stay, additional diagnostics or therapeutic 
procedures and therapies; moreover there are indirect social costs, like loss of 
productivity, long-term disability and mortality. Other financial repercussions include 
costs for containment of outbreaks, and changes of empirical antibiotic prescribing 
habits46. Nasal colonization still represent a risk factor for MRSA infection25, and the 
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primary natural reservoir of SA. Moreover, domestic animals, livestock and fomites 
may serve as adjunctive reservoirs2. The anterior nasal mucosa has traditionally 
been thought to be the most frequent site for the detection of SA colonization of 
healthy carriers, although recent studies demonstrated that screening at multiple 
body sites are more accurate2. Three patterns of asymptomatic SA carriers were 
individuated in the general population: persistent carriers, intermittent carriers and 
non-carriers who rarely harbor SA. The asymptomatic carriage of SA can be 
dynamic, and there were recently described asymptomatic colonized patients 
harboring more than one MRSA strain, and only a few of these patients had 
persistent colonization at the same anatomical site2. Moreover, a recent Portuguese 
study illustrated the presence of the major MRSA epidemic clones on bus47 allowing 
to consider surfaces as a vehicle of MRSA acquisition, while another study 
described waterborne transmission routes for SA and MRSA48.  
Due to the lack of a commonly accepted procedure for MRSA screening, and cost-
effectiveness benefits of such practice remains under debate, this Pediatric hospital 
chose to screen patients in case of necessity, e.g. outbreaks or particular cases. 
Healthcare givers of ICU wards are usually screened once/year, giving positive 
results in two cases, being the colonizing MRSA strains still under investigation. 
During this study, nasal screening was usually used in case of PVL infection: 
household contacts of positive patients were screened to search for reservoir. This 
procedure allowed to determine several cases of intra-familial transmission.  In one 
case it was documented the spreading of a PVL-positive SWP49, from the father 
showing a recurrent soft tissue infection, to the mother showing a nasal colonization; 
their infant developed an invasive infection with a pyopneumothorax. It was possible 
to document other two intra-familial cases, concerning mothers with reported 
recurrent soft tissue infections, transmitted to their childs. A PVL-positive SA was 
shared by two siblings, colonizing one and infecting the other. This situation was 
reflected in two different cases, the characterization of which is still ongoing. Soft 
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tissue infections should be taken into account, to avoid the spread of potentially 
dangerous PVL-positive strains.  
Hospital-acquired infections represent an important global healthcare problem, and 
PICU patients are traditionally at risk for pulmonary infections acquisition, especially 
in case of assisted ventilation. Almost all PICU patients monitored during this study 
already underwent a tracheotomy, and maintained the same MRSA strain during the 
whole study period, suggesting the possibility of a chronic infection. Those patients 
were admitted to the ICU with diagnosis compatible with a previously acquired 
infection. Although the small number of strains is not helpful defining the presence of 
endemic strains, ST128-MRSA-I or Southern Germany clone is the most 
represented epidemic lineage in PICU, according to recently published Italian data 
demonstrating  that this clone account for 57% of studied isolates3. Interestingly, 
CA-MRSA strains were also found: ST22-MRSA-IV PVL-negative, and ST148-
MRSA-V PVL-negative. ST22-MRSA-IV represent a known epidemic clone, while 
ST148-MRSA-V belongs to CC5; strains with the same genetic background but 
PVL-positive were sporadically isolated in Germany and Abu Dhabi9.  
During a previous prospective multi-center study involving CF center from all-over 
Italy and 178 patients4, SCCmec types were distribute as follows: 49.5% type I, 
1.2% type II, 3.9% type III and 31.4% type IV. Several chronically infected patients 
were monitored until 2012, becoming part of the present study. Changes occurred in 
SCCmec distribution, probably due to the differences in number of examined strains 
and geographic provenience. However, SCCmec type I remained the most 
represented HA-MRSA type. Although SCCmec type V appeared in 2010, CA-
MRSA percentage appears to be comparable with the previous study, being 29.6% 
in 2010, while  in 2011 was 25.9% and 27.2% in 2012. Three strains belonging to 
the same patient showed an undetermined SCCmec type, testing positive for 
different SCCmec types using different methods, thus remaining undetermined. 
Epidemic clones were found in examined CF patients, particularly those chronically 
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infected. Chronic infection represent one of the main aspect of MRSA  and CF: 
longitudinal study comprehending genetic background of isolate strains are rarely 
performed. To date, data obtained during this study represent an important starting 
point to understand molecular epidemiology of MRSA infecting CF patients. The 
importance of these findings is connected to the possibility to monitor patients 
consecutively for years, to have a continue surveillance on strains and their 
behavior. Eleven patients were monitored from first infection, as shown in Figure 7, 
three of which were infected by a CA-MRSA epidemic clone, which demonstrated 
the capability to establish chronic infections.  
Some unusual genetic background are shown in Figure 7: such as ST152 and ST8-
MRSA-V. ST152 is not common in CF Italian patients, it was recently described in 
2010 causing infective endocarditis50. Another patient showed to be chronically 
infected by the same strain, but PVL-negative. ST152 was recently described in 
Africa51, and previously in Denmark52, ex-Yugoslavia and Switzerland53. African 
isolates demonstrated to be SA, not MRSA, whilst strain from Denmark was MRSA 
with an impossible-to-type SCCmec. ST152 strains isolated during a seven-years 
chronic CF infection are characterized by agr  type I, as previously described 
strains53. The presence of a PVL-negative homologue strain may be explained with 
the excision of PVL, which is carried on a phage54 and thus to be excised. More 
studies are required to confirm this hypothesis.  
Another interesting case is represented by two siblings chronically infected by spa 
type t127, ST1, PVL-negative MRSA. This particular genotype was described as a 
porcine infective agent55. Noteworthy, another pig-related strain is responsible for a 
chronic infection in a CF patient: ST398-MRSA-V. This LA-MRSA was described in 
the Netherlands in people with frequent contact with farm animals; infections were 
only sporadically reported in farm workers and their family members56. The 
presence of this strains represents an important change in MRSA Italian 
epidemiology of CF patients.  
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Five CF patients were monitored before and after lung transplantation. The role 
played by MRSA in lung decline is not determinable due to the co-infection with 
Gram-negative species characterized by an high impact on lung function, such as 
Pseudomonas aeruginosa and Burkholderia cepacia complex. Although these 
species, including the rarely isolated Inquilinus limosus were isolated before and 
after lung transplantation, MRSA disappeared after lung transplantation. An 
explanation may be found in nasal sinus where Pseudomonas aeruginosa and other 
pathogens including MRSA are harbored. A recent report57 demonstrated 
persistence of identical P. aeruginosa genotypes in CF upper airways prior to and 
after lung transplantation, underlining risks of descending colonization of 
transplanted lungs with P. aeruginosa. MRSA presence was not cited, suggesting 
two different scenario: P. aeruginosa strains physically occupy nasal cavities 
avoiding the co-colonization with MRSA; those patients were not colonized by 
MRSA, thus after lung transplantation descending colonization appeared unlikely.  
The need of more detailed studies to shade a light on this question appears clear.  
Virulence factors represent an important aspect in SA and MRSA pathogenesis, and 
these species are able to produce an armamentarium of virulence factors including 
structural and secreted products, the regulation of which play a central role in 
pathogenesis played by agr quorum sensing system58. This system was recently 
investigated to determine its real importance in USA300 pathogenesis, showing that 
in USA300 there is an up-regulation of virulence factor genes comparing to HA-
MRSA59. At the moment obtained data should be integrated and correlated with 
clinical data, in order to assess correlation with patients’ status. Table 14 showed 
agr typing of collected strains; both PICU and CF chronically infected patients 
maintained the same agr type during the study period, suggesting that 
rearrangements are not common in a successful strain capable of a stable infection. 
IEC proteins are considered as virulence factor as well, being responsible for  
counteracting innate immunity. Those determinants are frequently encountered in 
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different MRSA genetic background9, but the effectiveness of their role remains 
unclear. Chronically infected patients tend to conserve the same IEC type, as well 
as agr type, but due to the number of tested strains is not possible to assess a 
correlation between IEC types and chronic infection. All types are represented both 
in chronic and in cleared first infections, suggesting the need of further studies on a 
larger number of MRSA isolates.  
ACME presence was tested in MRSA strains with compatible genetic background, 
and on all CoNS strains. Only one CF MRSA strain tested positive for ACME. The 
remaining 11 positive strains were CoNS, belonging to different ACME types. CoNS 
strains analysis did not give the expected results, being difficult to define CoNS as a 
virulence factor reservoir. Thus, CoNS role should be more carefully investigated 
with a larger number of strains, to confirm or to contest these preliminary data.  
PVL is a further virulence factor representing an important chapter in SA and MRSA 
history of virulence and pathogenesis. Several different bacteriophages encode 
PVL, and recent studies investigated the possibility of a correlation between phages 
and MRSA lineages54. Each SA lineage, and therefore MRSA, had lineage-specific 
restriction-modification systems, causing their independent evolution11. Figure 5 and 
6 show the evolutionary distances between different PVL partial sequences. It is 
interesting to note that pulmonary CF strains are in a separated branch comparing 
to the other strains, characterized by a different genotype. Both SA and MRSA PVL-
positive strains showed highly represented genetic backgrounds, such as ST22, 
ST8 (both MRSA and SA), ST5, being ST8 the most represented clone. CF strain 
belonged to ST152, a drastically different background described as SA in France, 
Togo and French West Indies60. These data concerning epidemiology of PVL-
positive strains confirmed the theory basing on which there is an association 
between PVL and successful lineages54. Moreover, the problem of unknown 
epidemiology and diffusion of PVL-producer strains spreading in the community 
remains an important issue.  
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This study allowed to collect strains and data for three years, being possible to 
investigate various aspects of 149 SA and MRSA strains. Molecular epidemiology 
delineated a picture representing all the major MRSA epidemic clones infecting CF 
patients together with new LA-MRSA strains isolated for the first time in Florence. 
PICU MRSA percentages confirmed good practice of infection control and 
surveillance, and the peculiarity of this third-level Pediatric hospital allowed to 
monitor MRSA chronically infected PICU patients. Surprisingly, these patients were 
infected both by HA- and CA-MRSA, although the more represented clone remained 
Southern Germany. CoNS isolates remained an un-resolved question, and their 
effective role should be investigate more intensively. 
Molecular epidemiology of PVL-positive strains revealed the presence of the most 
represented genetic backgrounds, shared by both MRSA and SA. 
It was interesting to note intra-familiar spreading starting from nasal colonization or 
soft tissue infections, with different repercussion on clinical status of pediatric 
patients, suggesting to pay attention to recurrent furuncles and soft tissue infections. 
New genotypes emerged, leading to the need of more accurate investigations 
involving phage insertion sites and complete genomes, to determine the origin and 
evolution of such strains, other than independent PVL acquisition in different 
lineages.  
This three-year study may be a starting point to examine the effectiveness of 
infection control measures as well as therapies and antimicrobial usage in a third-
level Pediatric hospital. Diffused clones may have been influenced in antimicrobial 
resistance by different therapeutic approaches, so that global epidemiology may 
represent a further advantage to set up improved therapies. Moreover, particular 
clones may be associated with chronic infections whilst other clones to transient 
ones, may be requiring different antimicrobial strategies. In conclusion, more studies 
are needed to evaluate the possible association between particular MRSA or SA 
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clones and clinical conditions in order to improve treatment strategies and possibly 
set up ad hoc therapeutic options.  
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